NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively

Rhea-AI Summary

NEXGEL (NASDAQ: NXGL) announced preliminary unaudited revenue for Q2 2024 at $1.4 million, marking a 20% year-over-year and 10% sequential increase. The company also issued revenue guidance for Q3 and Q4 2024: $2.2 million and $2.6 million, respectively, indicating significant year-over-year growth of 83% and 140%. CEO Adam Levy highlighted the record Q2 revenue despite lower contributions from CG Converting and Packaging due to facility expansion. The growth in contract manufacturing, driven by new relationships with large global corporations, and strong consumer demand for products like Silly George's Pop-On Lash, has positioned the company to potentially achieve positive cash flow from operations in the latter half of 2024.

Positive

• Q2 2024 revenue of $1.4 million, a 20% year-over-year increase.
• Q3 2024 revenue guidance of $2.2 million, an 83% year-over-year increase.
• Q4 2024 revenue guidance of $2.6 million, a 140% year-over-year increase.
• Growth in contract manufacturing due to new customer relationships with large global corporations.
• Strong consumer demand for new products, particularly Silly George's Pop-On Lash.

Negative

• Lower-than-normal revenues from CG Converting and Packaging due to facility expansion.

Financial Analyst

NEXGEL’s preliminary second-quarter revenue of $1.4 million signifies a year-over-year growth of 20% and a sequential increase of 10%. From a financial standpoint, this is notable as it indicates steady growth even amidst operational disruptions such as the facility move. Projected revenues for the third and fourth quarters are highly ambitious, with expected increases of 83% and 140% year-over-year respectively. These projections demonstrate management's confidence in the company's growth trajectory and its new customer relationships.

For a retail investor, it’s essential to understand that such significant growth expectations can be a double-edged sword. While it indicates potential for substantial value increase, it also sets high benchmarks. Any failure to meet these targets could lead to volatility in stock prices. Moreover, the company's move towards positive cash flow from operations is a important indicator of financial health, reducing reliance on external financing.

Investors should keep an eye on the company’s ability to manage operational challenges and execute on its growth strategies. Consistent performance in the next two quarters will be critical in validating these optimistic projections.

Market Research Analyst

From a market perspective, NEXGEL's revenue growth is underpinned by new customer relationships with large global corporations and the success of consumer products such as the Pop-On Lash product line. This suggests a robust underlying demand for both their contract manufacturing and consumer product segments.

Understanding the market dynamics, the success of new product launches like Pop-On Lash is indicative of strong market acceptance and consumer demand. Additionally, the anticipated growth despite not factoring in potential revenue from their relationship with AbbVie highlights the strength and diversification of their revenue streams.

However, investors should be mindful of market risks such as changing consumer preferences and competitive pressures. Continued innovation and maintaining strong customer relationships will be key to sustaining long-term growth.

Operational Efficiency Expert

The operational insights provided by NEXGEL's CEO highlight the impact of the move to an expanded facility. This move is likely aimed at scaling operations to meet increasing demand. While this has temporarily impacted revenue from CG Converting and Packaging, such strategic investments are necessary for long-term growth.

Efficiency in the new facility will be pivotal in supporting the ambitious revenue targets. Investors should watch for improvements in operational metrics such as throughput, capacity utilization and fulfillment rates. These will indicate whether the new facility is effectively contributing to the company’s growth objectives.

Operational disruptions are always a risk during such transitions, but if managed well, the expanded capacity can significantly boost productivity and revenue generation capabilities.

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024.

Based on preliminary and unaudited review, the Company anticipates:

• Second Quarter 2024 Revenue: $1.4 million, an increase of approximately 20% year-over-year and 10% sequentially
• Third Quarter 2024 Revenue: $2.2 million, an increase of 83% year-over-year
• Fourth Quarter 2024 Revenue: $2.6 million, an increase of 140% year-over-year
  

Adam Levy, CEO of NEXGEL, commented, “We are pleased to deliver record revenue for the second quarter of 2024 in spite of lower-than-normal revenues at CG Converting and Packaging due to our move into our newly expanded facility. We are also pleased to provide an outlook for our expected results for the second half of this year that has exceeded our expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is primarily due to new customer relationships with large global corporations. Additionally, many of our brands are also experiencing significant growth. Silly George is leading the way with strong consumer demand for our new Pop-On Lash product line released in May. While our projections for Q3 and Q4 do not yet include any revenue from our relationship with AbbVie, the growth we expect in the second half of this year positions us well to move to positive cash flow from operations.”

About NEXGEL, Inc.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal^®, Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Preliminary Second Quarter 2024 Results

This press release sets forth certain preliminary estimates of financial and operating results that we expect to report for the second quarter ended June 30, 2024. We are currently in the process of finalizing our financial results for the June 30, 2024 second quarter, and the preliminary estimated financial information presented above reflects various assumptions and estimates based upon preliminary information available to us as of the date of this press release. This information should not be viewed as a substitute for full unaudited financial statements prepared in accordance with accounting principles generally accepted in the United States for the second quarter ended June 30, 2024. Our independent registered public accounting firm has not reviewed this preliminary estimated financial information. As a result, it remains in all cases subject to change pending finalization. Items or events may be identified or occur after issuance of these preliminary results due to the completion of operational and financial closing procedures. In addition, final adjustments and other developments may arise that would require us to make material adjustments to this preliminary financial information. Therefore, our actual results may differ materially from the current expectations expressed in this release.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Valter@KCSA.com

FAQ

What is NEXGEL's preliminary revenue for Q2 2024?

NEXGEL's preliminary unaudited revenue for Q2 2024 is $1.4 million.

How much did NEXGEL's revenue grow year-over-year in Q2 2024?

NEXGEL's revenue grew by 20% year-over-year in Q2 2024.

What is NEXGEL's revenue guidance for Q3 2024?

NEXGEL's revenue guidance for Q3 2024 is $2.2 million.

What is NEXGEL's revenue guidance for Q4 2024?

NEXGEL's revenue guidance for Q4 2024 is $2.6 million.

Why were Q2 2024 revenues from CG Converting and Packaging lower?

Q2 2024 revenues from CG Converting and Packaging were lower due to a move into a newly expanded facility.

What factors contributed to NEXGEL's revenue growth?

Revenue growth was driven by new customer relationships with large global corporations and strong consumer demand for new products like Silly George's Pop-On Lash.